RT Journal Article
T1 The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
A1 Díaz-Beyá, M
A1 Brunet, S
A1 Nomdedéu, J
A1 Cordeiro, A
A1 Tormo, M
A1 Escoda, L
A1 Ribera, J M
A1 Arnán, M
A1 Heras, I
A1 Gallardo, D
A1 Bargay, J
A1 Queipo de Llano, M P
A1 Salamero, O
A1 Martí, J M
A1 Sampol, A
A1 Pedro, C
A1 Hoyos, M
A1 Pratcorona, M
A1 Castellano, J J
A1 Nomdedeu, M
A1 Risueño, R M
A1 Sierra, J
A1 Monzó, M
A1 Navarro, A
A1 Esteve, J
K1 MicroARNs
K1 Mitoxantrona
K1 Citarabina
K1 Etopósido
K1 Idarrubicina
K1 Leucemia mieloide aguda
K1 Citogenética
K1 Expresión génica
K1 Humanos
K1 Pronóstico
K1 Análisis citogenético
K1 Incidencia
K1 Cariotipo
K1 Análisis multivariante
K1 Recurrencia
K1 Anciano
AB Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
PB Nature Publishing Group
YR 2015
FD 2015-10-02
LK http://hdl.handle.net/10668/2049
UL http://hdl.handle.net/10668/2049
LA en
NO Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015; 5:e352
NO Journal Article;
DS RISalud
RD Apr 8, 2025